Navigation Links
Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Date:8/26/2009

LACHEN, Switzerland and HOBOKEN, N.J., Aug. 26 /PRNewswire/ -- Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide. Globally, 75% of the hemophilia cases go undiagnosed or untreated.

Octapharma AG, the third largest plasma products manufacturer in the world, recently brought together many of the most respected blood coagulation disorder researchers for two symposia on this important issue during the International Society on Thrombosis and Haemostasis (ISTH) Biennial Congress in Boston. Octapharma was one of only five Platinum Sponsors at the ISTH Congress, which attracted approximately 7,500 representatives of the medical and research community as well as many patients.

Clinical experts noted during the symposia that up to 40 percent of previously untreated patients (PUPs) with hemophilia A develop the most serious clinical complication of FVIII replacement therapy - inhibitory antibodies - which can result in uncontrolled hemorrhage, increased hospitalizations and joint damage, resulting in increased morbidity and mortality.

"We brought the international community together to confront this issue because our worldwide commitment to hemophilia A patients dates back to Octapharma's formation 25 years ago," said Octapharma AG Vice Chairman '/>"/>

SOURCE Octapharma AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
2. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
3. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
4. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
8. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... STUTTGART , Alemania, December 17, 2014 ... del año anterior, con un alto nivel de gasto ... pasado año fiscal 2013/14 (finalizado el 30 de septiembre ... por ciento a 4.287 millones de euros (año anterior: ... de la moneda desfavorables. Las ganancias (EBIT) crecieron un ...
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global ... Depository Trust Company (DTC) has made their final ... Chill on the Company,s stock effective December 15, ... common stock for depository and book entry transfer ... Company is now once again fully "DTC Eligible", ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... 8, 2011 INNOPHARMA LLC announced ... for levetiracetam injection (the generic equivalent of Keppra® injection from ... injectable drug, INNOPHARMA entered into a license agreement with X-GEN ... About INNOPHARMA: INNOPHARMA ...
... 8, 2011 Echo Therapeutics, Inc. (Nasdaq: ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, today announced the receipt of notices of issuance ... notices of registration for the trademarks PRELUDE and SYMPHONY. ...
Cached Medicine Technology:Echo Therapeutics Announces Multiple Patents and Trademark Grants 2Echo Therapeutics Announces Multiple Patents and Trademark Grants 3
(Date:12/20/2014)... 20, 2014 Developers of FCPX ... a new plugin for Final Cut Pro X entitled ... Volume 5 allows users to create hand drawn text ... Christina Austin, CEO of Pixel Film Studios. “TranSlice Volume ... while maintaining an easy to use interface.” , TranSlice ...
(Date:12/20/2014)... 20, 2014 Today, Balfleet.com, one of ... Christmas Sale, offering 50%-70% off on its Mother ... , The mother of the bride dresses from Balfleet.com ... is 24/7 accessible and takes pride in providing high ... “We are offering great discounts on our mother of ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up ... Sunday the 28th from 2pm-6pm at the Expo Center on ... Sarasota, FL. , Inquiries regarding time slots and signing up, ... the donating process, Sub Zero Ice Cream & Yogurt will ... cream. , About Sub Zero Ice Cream & Yogurt ...
(Date:12/19/2014)... SuperCloset raises the bar once again, with ... offer indoor growers the most efficient and effective indoor ... Rooms with the award winning SuperRooms for ... room setup. , The SuperClone Room features the most ... 50 . The SuperClone Room pairs this ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX ... cosmetic brand Juvéderm. Voluma XC treats volume loss in ... at Hendrick is pleased to be able to offer ... its clients. , Voluma is the first and only ... the mid-face and cheek area. This non-invasive treatment targets ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... , , NEWPORT, Ky., June 4 Xanodyne ... Valentino has been named to the position of President ... of the Company,s Board of Directors. In addition to ... $38 million led by MPM Capital. Current investors, participation ...
... PARK, Calif., June 4 XTENT, Inc. (Nasdaq: ... from the United States Food and Drug Administration (FDA) for ... pivotal clinical program, composed of two pivotal trials called CUSTOM ... the United States of its Custom NX(R) Drug Eluting ...
... California Cryobank , a leader in ... off-site collection center at Reproductive Medicine Associates ... center. The off-site collection center will provide fertility preservation ... , , Known worldwide for outstanding donor semen services, ...
... Ross ... the Center for Haitian Studies (CHS)/Greater Miami Health Education and Training Center (GMHETC). ... North Brunswick, NJ ... will add new clinical rotations in obstetrics and gynecology (OB/GYN) to its growing network ...
... ... Department published results from a promising yearlong study conducted with pediatric ... to keep them taking critical medication on schedule. By sending text ... patients experienced a rejection episode versus 12 patients prior to the ...
... ... and selfless acts of courage that help make the IMD one of Chicago’s safest places ... ... largest urban medical district, recognized its honored District Security Group (DSG) Members and their service ...
Cached Medicine News:Health News:Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 3Health News:Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 2Health News:Ross University School of Medicine Expands Clinical Rotations in Miami 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 3Health News:Illinois Medical District Recognizes Officers of its District Security Group 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and ... sample inoculation. With these slides, perform QC ... ,Laboratories enhance their education and training programs ... and interpretation, all on one slide! KWIK-QC ...
Each slide contains Giardia lamblia trophozoites applied as a mono-layer to the side....
Each slide contains a high yield of concentrated C. parvum oocysts within the positive control well. A negative control well is also included....
Medicine Products: